🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intermittent Hypoxia in Persons With Multiple Sclerosis

RecruitingNAAges 18 Years - 75 YearsAllShirley Ryan AbilityLab
NCT06276634 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS) * Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5 * Motor Functional System Scale (FSS) between 2-4 * Relapse free for at least 1 year * Age ≥ 18 years and ≤ 75 years * Safe to be scanned based on MRI questionnaire * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening Exclusion Criteria: * Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan * Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55) * History of epilepsy * Chronic obstructive pulmonary disease * Uncontrolled Sleep apnea * Pregnancy
💊

What it tests

  • Acute Intermittent Hypoxia
  • Sham-Acute Intermittent Hypoxia
📍

Where

1 site
Shirley Ryan AbilityLab
Chicago, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy